Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics.

By A. Letai, Michael C. Bassik, L. Walensky, M. Sorcinelli, S. Weiler, S. Korsmeyer. Cancer Cell, 2002

1,714 citations recorded by the source corpus.

The "BH3-only" proteins of the BCL-2 family require "multidomain" proapoptotic members BAX and BAK to release cytochrome c from mitochondria and kill cells. We find short peptides representing the alpha-helical BH3 domains of BID or BIM are capable of inducing oligomerization of BAK and BAX to release cytochrome c. Another subset characterized by the BH3 peptides from BAD and BIK cannot directly activate BAX, BAK but instead binds antiapoptotic BCL-2, resulting in the displacement of BID-like BH3 domains that initiate mitochondrial dysfunction. Transduced BAD-like and BID-like BH3 peptides also displayed synergy in killing leukemic cells. These data support a two-class model for BH3 domains: BID-like domains that "activate" BAX, BAK and BAD-like domains that "sensitize" by occupying the pocket of antiapoptotic members.

Subfields: Molecular Biology

View Paper: https://www.semanticscholar.org/paper/7c1269886fc7e97540965be9bce02cee0b9cce1e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

  1. Guido Kroemer
  2. Douglas R. Green
  3. Jerry M. Adams
  4. L. Galluzzi
  5. Simone Fulda
  6. A. Letai
  7. Beth Levine
  8. Suzanne Cory

Citations in the corpus